First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma. jkcvhl [Internet]. 2025 Apr. 25 [cited 2026 Apr. 17];12(2):27-36. Available from: https://jkcvhl.com/~jkcvhlco/index.php/jkcvhl/article/view/387